Tag:
cystic fibrosis
Latest Headlines
Latest Headlines
Vertex finds key support for cystic fibrosis drug in Europe
Vertex ($VRTX) has taken another step toward building a global franchise for treating cystic fibrosis. European regulatory advisers backed approval of the trailblazing drug Kalydeco for a subset of patients with the genetic disorder, paving the way for a likely go-ahead to market the drug in the EU.
Upstart biotech lures Vertex founder out of retirement
Alkeus and their lead program have hooked Josh Boger, who has decided to step back out of retirement to act as executive chairman for the fledgling Boston-based company after making a small investment.
Insmed stock soars after FDA ends hold on key lung drug
The company's stock price skyrocketed nearly 63% to $4.40 per share as of 12:07 p.m. ET after the announcement.
UPDATED: Vertex sizzles with upbeat PhII data on combo therapy for cystic fibrosis
The data indicate that Vertex might have a remedy for treating a large number of the 70,000 people worldwide with CF.
Johns Hopkins researchers find gene tied to CF secondary complication
Variations of the MSRA gene appear to affect whether newborns get a cystic fibrosis-related intestinal blockage known as meconium ileus.
U.K. CF gene therapy trials to test inhaled and viral delivery options
A cadre of U.K. researchers will begin a mid-stage trial later this month for a cystic fibrosis gene therapy delivered to the lungs with a nebulizer. They'll also begin a laboratory trial using a more advanced version of the same drug designed to ride in a modified virus to reach its target.
U.K. green lights study of pioneering gene therapy against cystic fibrosis
Researchers in the U.K. plan to launch a mid-stage clinical trial this month for an inhaled gene therapy to combat cystic fibrosis.
Langer upstart rakes in fresh venture cash for mucus-targeting drugs
An upstart biotech company with intriguing new formulation technologies and a roster of influential backers has rounded up $6.2 million in additional seed capital.
Forest Labs to launch inhaled lung infection drug in Germany
Forest Laboratories ($FRX) says it will use Germany to launch the European Union rollout of Colobreathe, its new dry powder inhalation treatment for cystic fibrosis-related lung infections, by...
One father's heartbreak inspired a $250M quest for a cure
Every new drug ever approved involved years of work by dedicated teams of investigators. In the case of the new cystic fibrosis drug Kalydeco from Vertex ( $VRTX ), the story also includes Boston
